InterCure and Cannasoul Forge Strategic Investment and Collaboration Partnerships
Share Purchase Agreement: InterCure has entered into a definitive Share Purchase Agreement with Cannasoul R&D, acquiring a 28% ownership stake on a fully diluted basis.
Future Ownership Potential: The agreement includes an exclusive option for InterCure to increase its ownership to 51% within two years.
Collaboration Agreement: A Collaboration Agreement has been established to formalize a partnership focused on the research, development, and commercialization of evidence-based cannabis therapeutics.
Strategic Partnership: This partnership aims to enhance the development of cannabis-based therapeutic solutions through combined expertise and resources.
Trade with 70% Backtested Accuracy
Analyst Views on INCR
About INCR
About the author
Trump's Marijuana Reclassification Expected to Propel This Cannabis ETF: Significant Momentum Increase
Trump's Executive Order Impact: A leveraged ETF focused on the American cannabis industry is expected to rise following President Trump's executive order aimed at easing federal restrictions on cannabis.
AdvisorShares MSOS Daily Leveraged ETF: The AdvisorShares MSOS Daily Leveraged ETF has seen a significant increase in its Momentum score, indicating strong investor interest amid regulatory changes, despite a recent pullback in its value.
Market Volatility: The fund experienced a notable decline of 50.59% after a previous drop of 26.91%, attributed to uncertainties regarding banking regulations in Trump's order, which were anticipated by the industry.
Overall Market Sentiment: Despite a high Momentum score, the ETF faces unfavorable price trends in the short, medium, and long term, reflecting mixed market sentiment towards cannabis stocks.
InterCure Joins High-End US Cannabis Market Through ISHI Agreement
InterCure's Acquisition of Botanico: InterCure Ltd. announced its acquisition of Botanico Ltd. (ISHI) to enhance its global cannabis portfolio, gaining access to advanced cultivation technologies and brand partnerships in the U.S. cannabis market.
Regulatory Context and Future Plans: The acquisition coincides with potential regulatory changes regarding cannabis scheduling in the U.S., and InterCure plans to complete the deal by Q1 2026, pending approvals, while integrating ISHI's leadership and assets.
InterCure Reveals Strategic Purchase of ISHI, Gaining Access to Top U.S. Cannabis Technology and Brands
InterCure's Strategic Acquisition: InterCure Ltd. has announced the acquisition of Botanico Ltd. (ISHI), a premium medical cannabis technology and brand company, enhancing its access to advanced cultivation technologies and partnerships with leading U.S. cannabis operators.
Regulatory Momentum and Market Potential: The acquisition coincides with the Trump administration's exploration of cannabis rescheduling, which could create significant opportunities for international cannabis companies like InterCure, positioning them to capitalize on the evolving U.S. cannabis landscape.
InterCure names Alexander Rabinovich as Chairman, replacing Ehud Barak
Leadership Change at InterCure: Mr. Ehud Barak will resign as Chairman of InterCure's board on February 13, 2025, with Mr. Alexander Rabinovich taking over after successfully leading the company as CEO for five years.
Company Recovery Efforts: InterCure is focused on restoring its Nir Oz facility, re-launching existing products, and expanding its pharmaceutical cannabis portfolio to better serve patient needs.
InterCure Names Alexander Rabinovich as Chairman Replacing Ehud Barak
InterCure Overview: InterCure Ltd. is highlighted in the news, showcasing its branding and market presence.
Recent Developments: The company has made significant strides in its operations and product offerings, reflecting growth and innovation in its sector.
InterCure has Secured Funding of NIS 66M to support the recovery of Nir Oz Facility
Funding for Expansion: InterCure Ltd. has secured funding commitments of NIS 66 million, potentially increasing to NIS 107 million, from key shareholders and a major Israeli bank to support the recovery and expansion of its facility post-war, aiming for growth in international markets like Germany, the UK, and Australia.
Post-War Recovery Plans: The company anticipates receiving additional compensation from Israeli authorities for war-related damages, which will aid in completing restoration efforts and returning to profitability by 2025, while also planning to double production capacity and enhance product offerings.
Trump's Marijuana Reclassification Expected to Propel This Cannabis ETF: Significant Momentum Increase
Trump's Executive Order Impact: A leveraged ETF focused on the American cannabis industry is expected to rise following President Trump's executive order aimed at easing federal restrictions on cannabis.
AdvisorShares MSOS Daily Leveraged ETF: The AdvisorShares MSOS Daily Leveraged ETF has seen a significant increase in its Momentum score, indicating strong investor interest amid regulatory changes, despite a recent pullback in its value.
Market Volatility: The fund experienced a notable decline of 50.59% after a previous drop of 26.91%, attributed to uncertainties regarding banking regulations in Trump's order, which were anticipated by the industry.
Overall Market Sentiment: Despite a high Momentum score, the ETF faces unfavorable price trends in the short, medium, and long term, reflecting mixed market sentiment towards cannabis stocks.
InterCure Joins High-End US Cannabis Market Through ISHI Agreement
InterCure's Acquisition of Botanico: InterCure Ltd. announced its acquisition of Botanico Ltd. (ISHI) to enhance its global cannabis portfolio, gaining access to advanced cultivation technologies and brand partnerships in the U.S. cannabis market.
Regulatory Context and Future Plans: The acquisition coincides with potential regulatory changes regarding cannabis scheduling in the U.S., and InterCure plans to complete the deal by Q1 2026, pending approvals, while integrating ISHI's leadership and assets.
InterCure Reveals Strategic Purchase of ISHI, Gaining Access to Top U.S. Cannabis Technology and Brands
InterCure's Strategic Acquisition: InterCure Ltd. has announced the acquisition of Botanico Ltd. (ISHI), a premium medical cannabis technology and brand company, enhancing its access to advanced cultivation technologies and partnerships with leading U.S. cannabis operators.
Regulatory Momentum and Market Potential: The acquisition coincides with the Trump administration's exploration of cannabis rescheduling, which could create significant opportunities for international cannabis companies like InterCure, positioning them to capitalize on the evolving U.S. cannabis landscape.
InterCure names Alexander Rabinovich as Chairman, replacing Ehud Barak
Leadership Change at InterCure: Mr. Ehud Barak will resign as Chairman of InterCure's board on February 13, 2025, with Mr. Alexander Rabinovich taking over after successfully leading the company as CEO for five years.
Company Recovery Efforts: InterCure is focused on restoring its Nir Oz facility, re-launching existing products, and expanding its pharmaceutical cannabis portfolio to better serve patient needs.
InterCure Names Alexander Rabinovich as Chairman Replacing Ehud Barak
InterCure Overview: InterCure Ltd. is highlighted in the news, showcasing its branding and market presence.
Recent Developments: The company has made significant strides in its operations and product offerings, reflecting growth and innovation in its sector.
InterCure has Secured Funding of NIS 66M to support the recovery of Nir Oz Facility
Funding for Expansion: InterCure Ltd. has secured funding commitments of NIS 66 million, potentially increasing to NIS 107 million, from key shareholders and a major Israeli bank to support the recovery and expansion of its facility post-war, aiming for growth in international markets like Germany, the UK, and Australia.
Post-War Recovery Plans: The company anticipates receiving additional compensation from Israeli authorities for war-related damages, which will aid in completing restoration efforts and returning to profitability by 2025, while also planning to double production capacity and enhance product offerings.
